Jefferies Group LLC Viking Therapeutics, Inc. Transaction History

Jefferies Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $27,423 - $40,940	12,997 Added 798.83%	14,624 $6,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $181,125 - $417,375	-52,500 Reduced 96.99%	1,627 $8,000
Q4 2019 Feb 13, 2020	SELL	$6.38 - $8.73 $47,658 - $65,213	-7,470 Reduced 12.13%	54,127 $434,000
Q3 2019 Nov 13, 2019	BUY	$6.55 - $8.6 $45,758 - $60,079	6,986 Added 12.79%	61,597 $424,000
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $177,476 - $245,967	23,139 Added 73.52%	54,611 $453,000
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $174,355 - $228,639	-23,002 Reduced 42.23%	31,472 $313,000
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $357,205 - $808,700	49,889 Added 1088.09%	54,474 $417,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $152,435 - $308,799	-15,715 Reduced 77.41%	4,585 $80,000
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $83,433 - $140,679	20,300 New	20,300 $89,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.